Affiliation:
1. Department of Social Work, Eastern Switzerland University of Applied Sciences, 9000 St. Gallen, Switzerland
Abstract
Recent developments regarding the pharmacology of psychoactive substances are significant for treating depressions or opioid addictions. Current theories, hypotheses, and models of drug effects assume a cause–effect narrative, which is based on a stimulus/response mechanism. These narratives prioritize effects rather than conscious experiences. In this sense, drug experiences are quickly subsumed into common categories and codes of biological determinism. If subjective experiences are in the focus of the research, it quickly becomes a link to mystical, spiritual, or transcendental narratives. These classifications lead to epistemological doublets (Gadamer). In this article, psychedelic experiences of drug users are analyzed in the frame of the pharmaco-analysis by Deleuze/Guattari. These framed psychedelic experiences are interpreted by means of a non-philosophical approach through philo-fictions (Laruelle), i.e., contradictory assumptions and hyperspeculations. In this respect, the aim of this article is to bring philo-fictions in relation to psychedelic experiences and to discuss them with models of information science, quantum mechanics, new materialism, and the philosophy of immanence. The result will be an open synthesis, with the assumption of further reflections on the agency, immanence, and the wholeness of matter.
Subject
History and Philosophy of Science,Philosophy
Reference76 articles.
1. Paulus, S., Scheidegger, A., Rabensteiner, J., and Egger, T. (2023). Psychosocial risks in the working environment—Approaches to formative risk assessment. ScienceOpen Res., preprint.
2. Erschöpfungsdepressionen: Zur zeitlich-dynamischen Erfassung von Krankheitsverläufen;Paulus;Psychother. Wissenschaft,2023
3. Ott, J. (1993). Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History, Natural Products.
4. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial;Griffiths;J. Psychopharmacol.,2016
5. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial;Ross;J. Psychopharmacol.,2016